Bahija Jallal, Immunocore CEO

FDA hur­ries up a quick ap­proval for the world's first TCR — af­ter a 14-year R&D trek

Over the 14 years since Im­muno­core was spun out of Medi­Gene in a quest to de­vel­op a gamechang­ing can­cer med, the biotech has raised record sums and un­der­gone a ma­jor shake­up on a long roller coast­er ride of val­u­a­tions for in­vestors. But they sur­vived and thrived and to­day they’re pop­ping the cham­pagne corks to cel­e­brate an FDA ap­proval of their first TCR drug.

Im­muno­core flagged the FDA’s green light for tebenta­fusp Wednes­day morn­ing by high­light­ing a se­ries of firsts.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.